Technical Data
Adeno-Associated Virus 2 (AAV2)
Suitable for use in Immunofluorescence microscopy, Immunohistochemistry, Immunoprecipitation, Neutralization Assay, Affinity chromatography and ELISA. Not suitable for use in Immunoblot. Other applications not tested.

Recommended Dilution:
Immunofluorescence: 1:20
Immunoprecipitation: 1:5
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG35F148Affinity Purified
50ug-20CBlue IceMouse
Adeno-associated virus capsid proteins and virus particles.
Purified by Protein A affinity chromatography.
Supplied as a lyophilized powder in PBS, 0.5% BSA, 0.09% sodium azide. Reconstitute with 1ml sterile, ddH2O or sterile 40-50% glycerol.
Recognizes AAV-2 found in human and monkey in ELISA. Also applicable to AAV-3. Specifically reacts wtih intact AAV particles, empty and full capsids. Recognizes a conformational epitope of assembled capsids not present in denatured capsid proteins and native but unassembled capsid proteins. Mjor reaction attributed to aa369-378 of AAV-2 capsids.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Wistuba A.,Weger S., Kern A., and Kleinschmidt J. (1995) Intermediates of adeno-associated virus type 2 assembly: Identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69, 5311-5319.
Wistuba A., Kern A., Weger S., Grimm D., and Kleinschmidt J. (1997) Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71, 1341-1352. Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidt J (1999) Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 6(7) 1322-1330. Wobus C.A., Hgle-Drr B., Girod A., Petersen G., Hallek M. and Kleinschmidt J.A. (2000) Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virology 74, 9281-9293.